Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 1 38Phase 1/2 21Phase EARLY_PHASE1 2Phase 3 2Phase 4 1

Status

Completed 35Active not recruiting 15Recruiting 7Unknown 3Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasm Metastasis 1Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Ipilimumab × Clear all
NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 3 Terminated
102 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡